Cargando…
Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
OBJECTIVES: Effective treatments for the critically ill patient with novel coronavirus disease 2019 are desperately needed. Given the role of cytokine release syndrome in the pathogenesis of coronavirus disease 2019-associated respiratory distress, therapies aimed at mitigating cytokine release, suc...
Autores principales: | Sirimaturos, Michael, Gotur, Deepa B., Patel, Samir J., Dreucean, Diane, Jakowenko, Nicholas, Cooper, Megan H., Brahmbhatt, Nishal, Graviss, Edward A., Nguyen, Duc T., Pingali, Sai Ravi, Lin, Jiejian, Musick, William L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531754/ https://www.ncbi.nlm.nih.gov/pubmed/33063035 http://dx.doi.org/10.1097/CCE.0000000000000232 |
Ejemplares similares
-
Pneumatocele and cysts in a patient with severe acute respiratory syndrome coronavirus 2 infection
por: Brahmbhatt, Nishal, et al.
Publicado: (2020) -
Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
por: Mert, Ali, et al.
Publicado: (2021) -
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021) -
Observer Status (Note by the Directorate Member for Administration)
Publicado: (1965) -
SARS-CoV-2-Related Acute Necrotizing Encephalopathy of Childhood With Good Response to Tocilizumab in an Adolescent
por: Ho, Jasmine H.Y., et al.
Publicado: (2023)